Patient professional reference
Professional Reference articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use. You may find one of our health articles more useful.
This is a white patch adhering to oral mucosa that cannot be removed by rubbing. It is usually a diagnosis of exclusion. The term should be exclusively reserved for idiopathic lesions when investigations fail to reveal any cause. The term carries no histological association.
Leukoplakia formerly also applied to vulval lesions but several international societies have developed a standardised nomenclature based on histopathological findings in vulval lesions. Leukoplakia, along with other terms, such as vulvar dystrophy, kraurosis vulvae, hyperplastic vulvitis and lichen sclerosus et atrophicus should no longer be used.
In their place the general term is 'non-neoplastic epithelial disorders', which are subdivided into three major categories: squamous cell hyperplasia, lichen sclerosus and other dermatoses. Therefore, suspicious white patches on the vulva should be biopsied to establish their correct classification and be treated accordingly. This is covered in the separate Lichen Sclerosus and Vulval Problems articles.
It is considered a pre-malignant lesion. The transformation rate is approximately 1%.
Factors most frequently blamed for the development of idiopathic leukoplakia include chronic irritation, candidiasis, vitamin A or vitamin B deficiency and endocrine disturbances. Tobacco use and alcohol consumption have been frequently cited but the evidence base supporting this has been questioned.
It may also be associated with other conditions such as:
- Lichen planus.
- Ill-fitting dentures.
- Secondary syphilis.
- Human papillomavirus infection.
- Prevalence - the estimated worldwide prevalence is 2%.
- Most cases of leukoplakia occur at age 50-70 years. Less than 1% of patients are under the age of 30 years.
- Leukoplakia is more common in men than in women, with a male-to-female ratio of 2:1.
- it occurs on mucous membranes in the mouth.
- It is seen as patches that are bright white and sharply defined.
- The surfaces of the patches are slightly raised above the surrounding mucosa.
- Individuals are not symptomatic.
There are three stages that have been described:
- The earliest lesion is non-palpable, faintly translucent and has white discolouration.
- Next, localised or diffuse, slightly elevated plaques with an irregular outline develop. These lesions are opaque white and may have a fine, granular texture.
- In some instances, the lesions progress to thickened, white lesions, showing induration, fissuring and ulcer formation.
Five clinical criteria demonstrate a particularly high risk of malignant change:
- The verrucous (speckled) type is considered high-risk.
- Erosion or ulceration within the lesion is highly suggestive of malignancy.
- The presence of a nodule indicates malignant potential.
- A lesion that is hard in its periphery is predictive of malignant change.
- Leukoplakia of the anterior floor of the mouth and undersurface of the tongue is strongly associated with malignant potential.
One study found that men over the age of 60 with oral leukoplakia on the lateral or ventral aspect of the tongue, who had a non-homogenous lesion with high-grade dysplasia, were most at risk of malignant change.
Any suspicious areas should be referred urgently for biopsy. Endoscopy has been used to improve the identification of oral lesions and the recognition of morphology suggestive of malignant change.
In all cases, the relative risk of malignant potential is determined by the presence of epithelial dysplasia upon histological examination.
Biomarkers of gene instability, such as aneuploidy and allelic imbalance, are predictive of cancer risk of oral pre-malignant lesions or intra-epithelial neoplasia but have not stood the test of time with respect to malignant change in oral leukoplakia. However, demonstration of recurrent genomic alterations by using techniques such as gene mapping may be of value.
There is no consensus on the management of oral leukoplakia.
Patients should abstain from alcohol and tobacco, although the evidence to support this advice has been questioned.
- Photodynamic therapy, the carotenoids beta-carotene and lycopene and systemic retinoic acid (vitamin A) have demonstrated limited effectiveness in speeding up the resolution of oral leukoplakia. The systemic side-effects of retinoic acid reduce the risk:benefit ratio for this indication considerably.
- Currently there is no evidence for effective treatment to prevent malignant change or recurrence.
- A Cochrane review concluded that whilst there may be some benefit from vitamin A and beta-carotene in healing oral lesions, relapses and adverse effects were common. Further research of existing non-surgical therapies is needed.
- Surgical excision of leukoplakia may be considered.
- Frequent clinical observation accompanied by photographic records is recommended. Because of the unpredictable behaviour of dysplastic lesions, immediately obtain a biopsy on any areas that are suggestive, or that change in appearance.
- Cryotherapy ablation and carbon dioxide laser ablation are also used:
- The area heals rapidly and apparently healthy mucosa is left behind. One study found that carbon dioxide laser ablation caused less pain and swelling than conventional surgery.
- Uncertainty remains regarding the risk of invasive carcinomas subsequently arising in sites previously treated. The recurrence rate after laser surgery has varied widely in the literature and studies have reported a range from 7.7% to 38.1%. It is thought that these differences have been dependent on differences in the variety and conditions of the laser beams, the follow-up period and race. Therefore, regular follow-up is obligatory after treatment.
- Erbium, chromium: yttrium-scandium-gallium-garnet (Er,Cr:YSGG) lasers appear to give less morphological distortion simulating cellular atypia than other types of lasers.
A 0.64% malignant transformation rate was found in one study of over 12,000 patients monitored for 12 years. Parameters associated with an increased risk of malignant transformation were female gender and smoking.
The malignant potential of non-homogeneous lesions is almost seven times higher compared to homogeneous types.
Despite excision, small dysplastic lesions can be followed by multiple carcinomas and a fatal outcome. In addition, some dysplastic lesions may have a worse prognosis than isolated carcinomas without leukoplakia. However, dysplastic lesions can regress spontaneously. Therefore, the behaviour of dysplastic lesions is unpredictable.
There is currently no reliable management protocol. Prolonged and close follow-up care is essential but the prognosis may still be poor.
This is associated with Epstein-Barr virus (EBV) and occurs mostly in people with HIV who are severely immunocompromised. It can affect patients who are HIV negative and many cases have been reported in heart, kidney and bone marrow transplant recipients and in patients with haematological malignancies.
The natural history of hairy leukoplakia is variable. Lesions may frequently appear and disappear spontaneously. Hairy leukoplakia is often asymptomatic and many patients are unaware of its presence. Some patients with hairy leukoplakia do experience symptoms including mild pain, dysaesthesia, alteration of taste and the psychological impact of its unsightly cosmetic appearance.
Management of hairy leukoplakia
As a benign lesion with low morbidity, hairy leukoplakia does not require specific treatment in every case. Indications for treatment include symptoms attributable to the lesion or a patient's desire to eliminate the lesion for cosmetic reasons. The variable natural history of the lesion and its tendency toward spontaneous resolution should be considered in any management decision.
- Systemic antiviral therapy, which usually achieves resolution of the lesion within 1-2 weeks of therapy.
- Topical therapy with podophyllin resin 25% solution, which usually achieves resolution after 1-2 treatment applications.
- Topical therapy with retinoic acid (tretinoin), which has been reported to resolve hairy leukoplakia.
- Ablative therapy, which can also be considered for small hairy leukoplakia lesions. Cryotherapy has been reported as successful but is not widely used.
Further reading and references
Feller L, Lemmer J; Oral Leukoplakia as It Relates to HPV Infection: A Review. Int J Dent. 20122012:540561. doi: 10.1155/2012/540561. Epub 2012 Feb 28.
Yanik EL, Katki HA, Silverberg MJ, et al; Leukoplakia, Oral Cavity Cancer Risk, and Cancer Survival in the U.S. Elderly. Cancer Prev Res (Phila). 2015 Sep8(9):857-63. doi: 10.1158/1940-6207.CAPR-15-0091. Epub 2015 Jul 9.
Brouns ER, Baart JA, Bloemena E, et al; The relevance of uniform reporting in oral leukoplakia: definition, certainty factor and staging based on experience with 275 patients. Med Oral Patol Oral Cir Bucal. 2013 Jan 118(1):e19-26.
Arduino P, Bagan J, El-Naggar A, et al; Urban legends series: oral leukoplakia. Oral Dis. 2013 Jan 11. doi: 10.1111/odi.12065.
Meisel P, Holtfreter B, Biffar R, et al; Association of periodontitis with the risk of oral leukoplakia. Oral Oncol. 2012 Sep48(9):859-63. doi: 10.1016/j.oraloncology.2012.02.022. Epub 2012 Mar 20.
Lopez-Jornet P, Camacho-Alonso F; Comparison of pain and swelling after removal of oral leukoplakia with CO(2) laser and cold knife: a randomized clinical trial. Med Oral Patol Oral Cir Bucal. 2013 Jan 118(1):e38-44.
Oral Leukoplakia; DermNet NZ
Shen ZY, Liu W, Zhu LK, et al; A retrospective clinicopathological study on oral lichen planus and malignant transformation: analysis of 518 cases. Med Oral Patol Oral Cir Bucal. 2012 Nov 117(6):e943-7.
Parlatescu I, Gheorghe C, Coculescu E, et al; Oral leukoplakia - an update. Maedica (Buchar). 2014 Mar9(1):88-93.
Liu W, Shi LJ, Wu L, et al; Oral cancer development in patients with leukoplakia--clinicopathological factors affecting outcome. PLoS One. 20127(4):e34773. doi: 10.1371/journal.pone.0034773. Epub 2012 Apr 13.
Kumar A, Cascarini L, McCaul JA, et al; How should we manage oral leukoplakia? Br J Oral Maxillofac Surg. 2012 Nov 14. pii: S0266-4356(12)00598-0. doi: 10.1016/j.bjoms.2012.10.018.
Yang SW, Lee YS, Chang LC, et al; Use of endoscopy with narrow-band imaging system in evaluating oral leukoplakia. Head Neck. 2012 Jul34(7):1015-22. doi: 10.1002/hed.21857. Epub 2011 Nov 3.
Cervigne NK, Machado J, Goswami RS, et al; Recurrent genomic alterations in sequential progressive leukoplakia and oral cancer: drivers of oral tumorigenesis? Hum Mol Genet. 2014 May 1523(10):2618-28. doi: 10.1093/hmg/ddt657. Epub 2014 Jan 8.
Ribeiro AS, Salles PR, da Silva TA, et al; A review of the nonsurgical treatment of oral leukoplakia. Int J Dent. 20102010:186018. doi: 10.1155/2010/186018. Epub 2010 Feb 23.
Lod G et al; Interventions for treating oral leukoplakia to prevent oral cancer, Cochrane, 2016.
Chiniforush N et al; Leukoplakia Removal by Carbon Dioxide Laser (CO2) Laser, Journal of Lasers in Medical Sciences Volume 3 Number 1 Winter 2012.
Seoane J, Gonzalez-Mosquera A, Lopez-Nino J, et al; Er,Cr:YSGG laser therapy for oral leukoplakia minimizes thermal artifacts on surgical margins: a pilot study. Lasers Med Sci. 2013 Jan 17.
Brzak BL, Mravak-Stipetic M, Canjuga I, et al; The frequency and malignant transformation rate of oral lichen planus and leukoplakia--a retrospective study. Coll Antropol. 2012 Sep36(3):773-7.
Leukoplakia; WHO International Agency for Research on Cancer, 2013
Reamy BV, Derby R, Bunt CW; Common tongue conditions in primary care. Am Fam Physician. 2010 Mar 181(5):627-34.
Khammissa RA, Fourie J, Chandran R, et al; Epstein-Barr Virus and Its Association with Oral Hairy Leukoplakia: A Short Review. Int J Dent. 20162016:4941783. doi: 10.1155/2016/4941783. Epub 2016 Mar 7.
Cho HH, Kim SH, Seo SH, et al; Oral hairy leukoplakia which occurred as a presenting sign of acute myeloid leukemia in a child. Ann Dermatol. 2010 Feb22(1):73-6. doi: 10.5021/ad.2010.22.1.73. Epub 2010 Feb 28.
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. Patient Platform Limited has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.